[music] We're back on Morning Trade Live. Let's focus on Novo Nordisk, the company announcing a new drug subscription [music] plan today. More on that in a second with Marley.But the chart has been nothing short of a disaster. The stock is trading near four-year lows and is [music] down more than 75% from its all-time high in late June of 2024. Look at that.So, that's the focus of the morning trade. Joining us now for a closer look, as we promised, is Marley. Good morning, Marley.just walk us through the de ...

The company is trying to win customers by offering a "lower, predictable monthly price†for its obesity drugs. ...

Novo Nordisk (NVO) on Tuesday announced a first-of-its-kind subscription program for its weight loss therapy Wegovy (semaglutide) available on telehealth platforms, including LifeMD (LFMD) and Hims & Hers (HIMS). As part of the program, cash-paying patients can choose 3-, 6-, or 12-month subscriptions ...

Novo Nordisk on Tuesday launched a multi-month subscription program for its Wegovy obesity drug products that aims to ensure cash-paying patients see lower, "predictable" monthly prices. Eligible patients can choose between three-, six- or 12-month subscriptions for the Wegovy injection or the two highest doses of the newly launched pill under the same brand name. Longer plans offer lower monthly pricing, and the company expects people to save up to $1,200 a year on the injection and as much as $600 a year ...

Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, February 4, 2026. REUTERS/Tom Little/File Photo Purchase Licensing Rights, opens new tab LONDON, March 31 (Reuters) - Novo Nordisk will launch a discounted subscription plan for U.S. Wegovy patients payin ...

Reporting by Yagnoseni Das in Bengaluru; Editing by Devika Syamnath Our Standards: The Thomson Reuters Trust Principles., opens new tab Purchase Licensing Rights Business Novo Nordisk further slashes prices of Ozempic, Wegovy in India to better compete as generics enter | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. REUTERS/Hollie Adams Purchase ...

整理 | GLP1减重宝典内容团队 但现在，行业开始转向另一个问题。真正决定下一轮竞争格局的，未必只是最强疗效，而是谁能够成为更多患者进入治疗体系的第一 步。 诺和诺德判断，到2030年，口服剂型将拿下全球超过三分之一的肥胖市场，这意味着在大药厂眼里，口服已经不再只是注射剂之外的补 充选项，而是未来市场基础盘的重要组成部分。 这背后最关键的变化，在于肥胖药市场正在从单纯的疗效竞争，转向入口竞争。 对大量患者而言，减重治疗最大的门槛，并不总是疗效是否足够强，而是是否愿意真正开始。有人对注射始终存在心理障碍，有人很难 接受长期每周打针的治疗方式，也有人虽然有减重意愿，但并没有准备好一开始就进入强干预状态。相较之下，口服药更接近日常慢病 管理的习惯，也更容易被视为一种可以尝试、可以持续、可以融入生活的选择。 这正是口服剂型最重要的商业意义。它改变的不是天花板，而是地板。它首先争夺的，不是那批最重度、最复杂、最需要强化治疗的人 群，而是那些原本可能根本不会进入减重药物治疗体系的人。只要这部分人群被大规模带进来，整个市场的底盘就会被重新抬高。 过去几年，肥胖药市场最受关注的问题一直是谁更强。谁能把减重幅度做得更高，谁能 ...

2026 年 3 月 31 日 证券研究报告 估值方面，截至 2026 年 3 月 27 日，医药生物行业 PE（TTM 整体法， 剔除负值）为 29.30x（上期末 30.34x），估值下行，低于均值。医药 生物申万三级行业 PE（TTM 整体法，剔除负值）前三的行业分别为 疫苗（52.48x）、化学制剂（39.95x）、医院（38.35x），中位数为 31.21x，医药流通（13.52x）估值最低。 XXXX@gwgsc.com 重要行业资讯： ◆NMPA：开展医疗器械临床创新成果转化"春雨行动" 医药生物行业双周报 2026 年第 6 期总第 155 期 2026 年 AACR 年会即将举行 创新药板块迎来重要数据催化窗口 行业回顾 评级变动 维持评级 本报告期医药生物行业指数跌幅为 1.26%，在申万 31 个一级行业中 位居第 4，跑赢沪深 300 指数（-3.57%）。从子行业来看，医疗研发 外包、化学制剂涨幅居前，涨幅分别为 2.78%、1.36%；医院、血液 制品跌幅居前，跌幅分别为 8.42%、6.69%。 行业走势： ◆强生：口服 IL-23R 拮抗剂"Icotrokinra"获美国 FD ...

2026 年 3 月 31 日 证券研究报告 医药生物行业双周报 2026 年第 6 期总第 155 期 2026 年 AACR 年会即将举行 创新药板块迎来重要数据催化窗口 行业回顾 评级变动 维持评级 ◆诺华：拟在华投资超 33 亿元人民币 投资建议： 1/24 近期，医药生物板块催化因素持续累积，药械创新仍是当前的核心主 线。一方面，国内政策端继续释放积极信号，NMPA 将在全国范围内 组织实施为期三年的"医疗器械临床创新成果转化"春雨行动"，进 一步强化对创新器械成果转化和产业化落地的支持；另一方面，海外 公司地址：北京市丰台区凤凰嘴街 2 号院 1 号楼中国长城资产大厦 16 层 分析师 胡晨曦 本报告期医药生物行业指数跌幅为 1.26%，在申万 31 个一级行业中 位居第 4，跑赢沪深 300 指数（-3.57%）。从子行业来看，医疗研发 外包、化学制剂涨幅居前，涨幅分别为 2.78%、1.36%；医院、血液 制品跌幅居前，跌幅分别为 8.42%、6.69%。 行业走势： 估值方面，截至 2026 年 3 月 27 日，医药生物行业 PE（TTM 整体法， 剔除负值）为 29.30x（上期末 30 ...

Novo Nordisk, one of the principal suppliers of GLP-1 weight-loss medication, has handed a board role to the chief executive of Mars. Poul Weihrauch is to be a “board observer” at the pharma group, which markets GLP-1 drugs under brands including Ozempic and Wegovy. GLP-1 medication, associated with appetite suppression, was first approved to treat Type-2 diabetes in the US more than 15 years ago and for the treatment of obesity around a decade ago. However, with more consumers turning to the drugs to ...